Vanda Pharmaceuticals
VNDA
140 hedge funds and large institutions have $213M invested in Vanda Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 49 increasing their positions, 45 reducing their positions, and 28 closing their positions.
23% more capital inflows, than outflows
Capital inflows: $21.1M | Capital outflows: $17.1M
9% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 45
0.86% more ownership
Funds ownership: 75.6% → 76.46% (+0.86%)
5% less funds holding
Funds holding: 147 → 140 (-7)
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
97% less call options, than puts
Call options by funds: $197K | Put options by funds: $6.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.29M |
| 2 |
Two Sigma Advisers
New York
|
+$2.51M |
| 3 |
Citigroup
New York
|
+$2.12M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.87M |
| 5 |
Two Sigma Investments
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schonfeld Strategic Advisors
New York
|
-$1.74M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.57M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$1.39M |
| 4 |
Goldman Sachs
New York
|
-$1.26M |
| 5 |
Trexquant Investment
Stamford,
Connecticut
|
-$882K |
VNDA Hedge Fund Activity: Q2 2025 in Review
140 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2025, worth a combined $213M — up 5.1% from $202M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of VNDA and 21 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 49 added.
The largest buyer was Millennium Management, adding an estimated $4.29M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.74M sold.
- 140 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2025, down from 147 in Q1 2025.
- Funds reported $213M of Vanda Pharmaceuticals stock for Q2 2025, up 5.1% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q2 2025 and 28 closed out, a net change of -7 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $4.29M added.
- The largest Vanda Pharmaceuticals seller in Q2 2025 was Schonfeld Strategic Advisors, an estimated $1.74M sold.
Based on aggregated 13F filings for Q2 2025.